The characterization of over 300 mutants, derived from two strains of poliovirus type 3 and selected for resistance to neutralization by monoclonal antibodies, has led to the further definition of the major antigenic site involved in neutralization. The site encompasses amino acids 89 to 100 of VP1. A subsidiary antigenic site near the C-terminus of VP1 has been identified for the Sabin vaccine strain of poliovirus type 3. Of 59 monoclonal antibodies to poliovirus type 3 examined, 27 had virus-neutralizing activity and 25 of these were identified as directed against the major site on VP1 (designated site 1), indicating the immunodominant role of this site. One of the six monoclonal antibodies that recognized the subsidiary antigenic site on VP1 (designated site 2) possessed virus-neutralizing activity. The identification of the principal antigenic site of the virus provides a rational basis for attempts at the development of synthetic oligopeptide vaccines against poliovirus type 3.
EvansD. M. A.,
MinorP. D.,
SchildG. C.,
AlmondJ. W.1983; Critical role of an eight amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature, London 304:459–462
FergusonM.,
QiYi-Hua.,
MinorP. D.,
MagrathD. I.,
SpitzM,
SchildG. C.1982; Monoclonal antibodies specific for the Sabin vaccine strain of poliovirus. Lancet ii:122–124
FergusonM.,
MinorP. D.,
MagrathD. L.,
Yi-HuaQi,
SpitzM.,
SchildG. C.1984; Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies. Journal of General Virology 65:197–201
MinorP. D.,
SchildG. C.,
FergusonM.,
MackayA.,
MagrathD. I.,
JohnA.,
YatesP. J.,
SpitzM.1982; Genetic and antigenic variation in type 3 polioviruses: characterization of strains by monoclonal antibodies and T1 oligonucleotide mapping. Journal of General Virology 61:167–176
MinorP. D.,
SchildG. C.,
BootmanJ.,
EvansD. M. A.,
FergusonM.,
ReeveP.,
SpitzM.,
StanwayG.,
CannA. J.,
HauptmannR.,
ClarkeL. D.,
MountfordR. C.,
AlmondJ. W.1983; Location and primary structure of a major antigenic site for poliovirus neutralization. Nature, London 301:674–678
StanwayG.,
CannA. J.,
HauptmannR.,
HughesP.,
ClarkeL. D.,
MountfordR. C.,
MinorP. D.,
SchildG. C.,
AlmondJ. W.1983; The nucleic acid sequence of poliovirus type 3 Leon 12a1b: comparison with type 1. Nucleic Acids Research 11:5629–5643
StanwayG.,
HughesP. J.,
MountfordR. C.,
ReeveP.,
MinorP. D.,
SchildG. C.,
AlmondJ. W.1984; Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon/12a1b. Proceedings of the National Academy of Sciences, U. S. A 81:1539–1543
WychowskiC.,
Van Der WerfS.,
SiffertO.,
CrainicR.,
BruneauP.,
GirardM.1983; A poliovirus type 1 neutralization epitope is located within amino acid residues 93–104 or viral capsid polypeptide VP1. EMBO Journal 2:2019–2024